Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 270

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial

Open access
Tebas, Pablo, Yang, ShuPing, Boyer, Jean D., Reuschel, Emma L., Patel, Ami, Christensen-Quick, Aaron, Andrade, Viviane M., Morrow, Matthew P., Kraynyak, Kimberly, Agnes, Joseph, Purwar, Mansi, Sylvester, Albert, Pawlicki, Jan, Gillespie, Elisabeth, Maricic, Igor, Zaidi, Faraz I., Kim, Kevin Y., Dia, Yaya, Frase, Drew, Pezzoli, Patrick, Schultheis, Katherine, Smith, Trevor R.F., Ramos, Stephanie J., McMullan, Trevor, Buttigieg, Karen, Carroll, Miles W., Ervin, John, Diehl, Malissa C., Blackwood, Elliott, Mammen, Mammen P., Lee, Jessica, Dallas, Michael J., Brown, Ami Shah, Shea, Jacqueline E., Kim, J.Joseph, Weiner, David B., Broderick, Kate E., Humeau, Laurent M. · 2021 · EClinicalMedicine

Abstract

Background A vaccine against SARS-CoV-2 is of high urgency. Here the safety and immunogenicity induced by a DNA vaccine (INO-4800) targeting the full length spike antigen of SARS-CoV-2 are described. Methods INO-4800 was evaluated in two groups of 20 participants, receiving either 1.0 mg or 2.0 mg of vaccine intradermally followed by CELLECTRA® EP at 0 and 4 weeks. Thirty-nine subjects completed both doses; one subject in the 2.0 mg group discontinued trial participation prior to receiving the second dose. ClinicalTrials.gov identifier: NCT04336410. Findings The median age was 34.5, 55% (22/40) were men and 82.5% (33/40) white. Through week 8, only 6 related Grade 1 adverse events in 5 subjects were observed. None of these increased in frequency with the second administration. No serious adverse events were reported. All 38 subjects evaluable for immunogenicity had cellular and/or humoral immune responses following the second dose of INO-4800. By week 6, 95% (36/38) of the participants seroconverted based on their responses by generating binding (ELISA) and/or neutralizing antibodies (PRNT IC 50 ), with responder geometric mean binding antibody titers of 655.5 [95% CI (255.6, 1681.0)] and 994.2 [95% CI (395.3, 2500.3)] in the 1.0 mg and 2.0 mg groups, respectively. For neutralizing antibody, 78% (14/18) and 84% (16/19) generated a response with corresponding geometric mean titers of 102.3 [95% CI (37.4, 280.3)] and 63.5 [95% CI (39.6, 101.8)], in the respective groups. By week 8, 74% (14/19) and 100% (19/19) of subjects generated T cell responses by IFN-ɣ ELISpot assay with the median SFU per 10 6 PBMC of 46 [95% CI (21.1, 142.2)] and 71 [95% CI (32.2, 194.4)] in the 1.0 mg and 2.0 mg groups, respectively. Flow cytometry demonstrated a T cell response, dominated by CD8 + T cells co-producing IFN-ɣ and TNF-α, without increase in IL-4. Interpretation INO-4800 demonstrated excellent safety and tolerability and was immunogenic in 100% (38/38) of the vaccinated subjects by eliciting either or both humoral or cellular immune responses. Funding Coalition for Epidemic Preparedness Innovations (CEPI).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.eclinm.2020.100689

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 31 references

Cited by

See all 270

Metadata

Authors
Tebas, P., Yang, S., Boyer, J. D., Reuschel, E. L., Patel, A., Christensen-Quick, A., Andrade, V. M., Morrow, M. P., Kraynyak, K., Agnes, J., Purwar, M., Sylvester, A., Pawlicki, J., Gillespie, E., Maricic, I., Zaidi, F. I., Kim, K. Y., Dia, Y., Frase, D., Pezzoli, P., Schultheis, K., Smith, T. R. F., Ramos, S. J., McMullan, T., Buttigieg, K., Carroll, M. W., Ervin, J., Diehl, M. C., Blackwood, E., Mammen, M. P., Lee, J., Dallas, M. J., Brown, A. S., Shea, J. E., Kim, J. J., Weiner, D. B., Broderick, K. E., & Humeau, L. M.
Venue
EClinicalMedicine
Publisher
Elsevier BV
Published
2021-01
Volume
31
Pages
100689
ISSN
2589-5370 (ISSN-L)
OpenAlex
W3115068672
Cited by
270
References
31
FWCI
6.58
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial. https://app.cochat.ai/papers/10.1016/j.eclinm.2020.100689
The paper
Tebas, P., Yang, S., Boyer, J. D., Reuschel, E. L., Patel, A., Christensen-Quick, A., Andrade, V. M., Morrow, M. P., Kraynyak, K., Agnes, J., Purwar, M., Sylvester, A., Pawlicki, J., Gillespie, E., Maricic, I., Zaidi, F. I., Kim, K. Y., Dia, Y., Frase, D., . . . Humeau, L. M. (2021). Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial. EClinicalMedicine. https://doi.org/10.1016/j.eclinm.2020.100689

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.